Julie Delyon
Julie Delyon is an expert in Oncology at Hôpital Saint-Louis (France). Julie Delyon has authored 137 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 467 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Dermatology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2011 - 2026
Number : 137
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Correction: A differential process mining analysis of COVID-19 management for cancer patients. PMID 41847696 — neoplasms, covid-19 | Front Oncol | 2026 | 0 |
| Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study. PMID 41396687 — skin, cells, safety, melanoma, neoplasms, sarcoma, immune checkpoint inhibitors, hiv, therapeutics, skin neoplasms | Oncologist | 2025 | 0 |
| Immune Checkpoint Inhibitor-Induced Lipodystrophy. PMID 40202750 — lipodystrophy, skin diseases, immune checkpoint inhibitors | JAMA Dermatol | 2025 | 0 |
| PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors. PMID 39574163 — cells, protein isoforms, melanoma, neoplasms, therapeutics | Cell Commun Signal | 2024 | 0 |
| Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk-benefit ratio. PMID 38012894 — risk, therapeutics, neoplasms, neoadjuvant therapy, immune checkpoint inhibitors | Lancet Oncol Top journal | 2023 | 1 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map